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Background: High-grade gliomas including glioblastoma multiforme (GBM) are among the most malignant and
aggressive of tumors, and have a very poor prognosis despite a temozolomide-based intensive treatment.
Therefore, a novel therapeutic approach to controlling recurrence is needed. In the present study, we investigated
the effect of activated dendritic cell (DC) (α-type-1 polarized DC)-based immunotherapy on high-grade glioma
patients with the HLA-A2 or A24 genotype.
Methods: Nine patients with recurrent high-grade gliomas including 7 with GBMs who fulfilled eligibility criteria
were enrolled into a phase I study of monocyte-derived DC-based immunotherapy. HLA-genotyping revealed 1
case of HLA-A*0201 and 8 cases of A*2402. Enriched monocytes obtained using OptiPrepTM from leukapheresis
products on day1, were incubated with GM-CSF and IL-4 in a closed serum-free system, and activated on day6 with
TNF-α, IL-1β, IFN-α, IFN-γ, and poly I/C. After pulsing with a cocktail of 5 synthetic peptides (WT-1, HER2, MAGE-A3,
and MAGE-A1 or gp100) restricted to HLA-A2 or A24 and KLH, cells were cryopreserved until used. Thawed DCs
were injected intradermally in the posterior neck at a dose per cohort of 1.0, 2.0 and 5.0× 107/body.
Results: The frequency of CD14+ monocytes increased to 44.6% from 11.9% after gradient centrifugation. After a
7-day-incubation with cytokines, the mean percentage of DCs rated as lin-HLA-DR+ in patients was 56.2 ± 19.1%.
Most DCs expressed high levels of maturation markers, co-stimulatory molecules and type-1 phenotype (CD11c
+HLA-DR+) with a DC1/2 ratio of 35.6. The amount of IL-12 produced from activated DCs was 1025 ± 443 pg/ml per
105 cells. All 76 DC injections were well tolerated except for transient liver dysfunction with grade II. Six patients
showed positive immunological responses to peptides in an ELISPOT assay, and positive skin tests to
peptide-pulsed DC and KLH were recognized in 4 cases. The clinical response to DC injections was as follows :1 SD
and 8 PD. Interestingly, the SD patient, given 24 DC injections, showed a long-term recurrence-free and
immunological positive response period.
Conclusions: These results indicate peptide cocktail-treated activated α-type-1 DC-based immunotherapy to be a
potential therapeutic tool against recurrent high-grade glioma with mainly HLA-A*2402.
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Table 1 Phase I study of DC-based therapy against
high-grade glioma




1 69 M ST, CT 1 GBM (IV)
2 49 M ST, CT, RT 0 AO (III)
3 38 M ST, CT, RT 2 GBM (IV)
4 32 F CT, RT, 2 AA (III)
5 61 M ST, CT, RT 1 GBM (IV)
6 32 M ST, CT, RT 1 GBM (IV)
7 73 M ST, CT, RT 1 GBM (IV)
8 53 F ST, CT, 1 GBM (IV)
9 31 M ST, CT, 1 GBM (IV)
ST; surgical therapy, CT; chemotherapy, RT; radiation therapy.
GBM; glioblastoma multiforme, AO; anaplastic oligodendroglioma.
AA; anaplastic astrocytoma.
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High-grade gliomas including glioblastoma multi-
forme (GBM) are among the most malignant and ag-
gressive of tumors, and have a very poor prognosis
and high recurrence rate with a mean survival time
of less than 2 years even with the recent develop-
ment of an intensive temozolomide (TMZ)-based
treatment protocol [1,2]. Thus, a novel therapeutic
approach to controlling recurrence and overcoming
resistance to treatment is urgently needed for high-
grade glioma patients.
Novel therapeutic approaches to controlling tumor
recurrence by targeting crucial signaling molecules like
TGF-β [3], JAK-STAT [4-6] and WINT [7], adhesion
molecules like αβ integrin [8], and pro-angiogenic fac-
tors like VEGF and VEGFR [9], have been tried. How-
ever, a breakthrough has yet to be made. Meanwhile,
immunotherapy is also recognized as a therapeutic tool
against high-grade gliomas, and preliminary studies trying
to suppress recurrence have been reported [10-13]. DC-
based vaccines against high-grade gliomas have moderate
effects in terms of a patient`s performance status (PS) or
quality of life (QOL) [14], however the impact of such
approaches is still not obvious because of a weak vaccine
effect and poor PS.
Since the Provenge cancer vaccine against metastatic
prostate cancer was approved by the FDA based on a its
impact on overall survival in a phase III randomized
study, the life-prolonging effect of DC vaccines without
significant side effects has been receiving attention
[15,16]. Additionally, an important point regarding a
successful DC-based cancer vaccine is still the full mat-
uration of DCs because it affects significantly the func-
tion of DCs and anti-tumor effect directly. However, a
precise evaluation for maturation has not established
and therefore various factors are utilized as so-call mat-
uration markers.
In the present study, we have manufactured α-
type-1 polarized DCs, activated by a combination of
maturation reagents like TNF-α, IL-1β, IFN-α, IFN-γ
and polyI/C. Αlpha-type-1 polarized DCs were first
reported by Mailliard et al., who found a large
amount of IL-12 in supernatant [17]. Additionally,
Okada et al. reported that an α-type-1 polarized DC
vaccine treated with HLA-A2 peptides was useful for
controlling relapse in cases of high-grade glioma
[18]. Based on these results, we considered that an
α-type-1 DC vaccine also could have a therapeutic
effect on HLA-A24+ glioma patients, and performed
a phase I clinical trial of HLA-A24-restricted peptide
cocktail-pulsed DC-based immunotherapy against
high-grade glioma. Here we describe the safety and
efficacy of an α-type-1 DC-based vaccine against re-
current high-grade glioma.Methods
Patient characteristics and eligibility criteria
Nine patients with recurrent high- grade glioma were
enrolled in a phase I clinical trial of a peptide cocktail-
pulsed α-type1-polarized DC-based vaccine approved
by the Institutional Review Board of the Shizuoka Cancer
Center, Shizuoka, Japan. All patients gave written informed
consent. Patients` characteristics are listed in Table 1.
Inclusion criteria were: i) histological diagnosis of high-
grade glioma (WHO grade III or IV) [19], ii) poor response
to standard treatment [surgical therapy (ST) + radiation
therapy (RT) + temozolomide], iii) 20 y.o. ≦ age < 80
y.o., iv) performance status ≦ 2, v) evaluable lesions
in imaging diagnosis, vi) HLA genotyping ; HLA-A2
or A24, vii) no severe systemic organ dysfunction, viii)
no severe hematostatic dysfunction, ix) informed consent
obtained from patients, and x) life expectancy > 6 months.
Minimum doses of corticosteroid (dexamethasone up to 1
mg/day) were permitted for patients with neurological
deficits due to mass effects by the lesions.
Exclusion criteria were : i) severe systemic infection
and organ failure, ii) pregnancy, iii) severe immuno-
logical disorders (autoimmune disease, immunosuppres-
sion), iv) multiple cancers, and v) anaphylaxis to synthetic
peptides. All the patients received intradermally (i.d.) 4 DC
vaccines at the posterior neck weekly, and toxicity was
checked. DCs were injected in a dose-escalation de-
sign at a dose level per cohort of 1.0, 2.0, and 5.0 ×107/
body/shot. The injected DC number was calculated from
the percentage of Lin-HLA-DR+ gated populations in a
FACS analysis.
Preparation of DCs and peptides
The procedures for preparing the DC vaccine were per-
formed within a high efficiency particle arrestance
(HEPA)-filter clean-air barriered good manufacturing
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ation procedure (SOP) for DC vaccine production was
established according to institutional GMP-based guide-
lines. The procedures have been described before [20].
Briefly, leukapheresis products were washed and centri-
fuged using density-adjusted OptiPrep™ (Axis-Shield
PoC, Oslo, Norway), and the monocyte layer at the top
was retrieved. On day1, cells were transferred to an
X-fold culture bag (Nexell, Irvine, CA) and cultured
in the presence of GM-CSF at 50 ng/ml (CellGenix,
Freiburg, Germany) and IL-4 at 50 ng/ml (CellGenix) in X-
VIVO15 serum-free medium (Biowhittaker, Walkersville,
MD). On day6, cells were activated by the addition of TNF-
α at 10 ng/ml (CellGenix), IL-1β at 10 ng/ml (CellGenix),
IFN-α at 3000 U/ml (Dainippon Sumitomo Pharma Co.
Ltd, Osaka, Japan), IFN-γ at 1000 U/ml (Shionogi & Co.
Ltd, Osaka, Japan), and poly I/C at 20 μg/ml (Amersham
Biosciences Corp., Piscataway, NJ). On day8, harvested
cells were pulsed with a cocktail of 5 synthetic peptides
(25 μg/ml each) restricted to HLA A2 or A24 and KLH
(25 μg/ml, Intracell, Frederick, MD). Finally, DC-enriched
cells were washed and cryopreserved in Cryocyte bags
(Baxter Healthcare Co., Deerfield, IL) until used. The pur-
ity of CD14+ cells was evaluated with a flow cytometer
(FACSCalibur, Becton-Dickinson Co., CA) before and
after OptiPrep™ separation. The percentage of DCs was
rated as the lin-HLA-DR+ population (lineage antibodies
including CD3, CD14, CD16, CD19, CD20, CD56 ; BD
Biosciences, San Jose, CA). The frequencies of the DC-
related markers were determined using various antibodies
for CD1a, CD11c, CD33, CD40, CD54, CD80, CD86,
CD123, CD205, CD207, CMRF44, CMRF56, E-cadherin
CCR7, HLA-class I, and HLA-DR (BD Biosciences). The
ratio of DC1 (CD11c+HLA-DR+) and DC2 (CD123+HLA-
DR+) was calculated using a flow cytometric analysis
reported by Ferrari et al. [21].
The following peptides restricted to HLA-A2 or
A24 were synthesized according to GMP standards by
Multiple Peptide Systems, CA: HLA-A2: WT1126-134
(RMFPNAPYL), WT1235-243 (CMTWNQMNL), gp100209-
217 (IMDQVPFSV), HER2369-377 (KIFGSLAFL), MAGE-
A3271-279 (FLWGPRALV) ; HLA-A24: WT1235-243M
(CYTWNQMNL), WT1235-243 (CMTWNQMNL),
HER263-71 (TYLPTNASL), MAGE-A1135-143 (NYKHCF
PEI), MAGE-A3195-203 (IMPKAGLLI).IL-12p70 production assay
Cultured mature DCs were collected, and plated in a
round-bottomed 96-well microplate at 5 × 104 cells/well.
To stimulate IL-12p70 production by DCs, a CD40
ligand-expressing mouse plasmacytoma cell line, J558,
was added at 1 × 105/well. CD40L-transfected J558 cells
were kindly supplied by Dr. Kalinsky, the Universityof Pittsburgh Cancer Institute, Pittsburgh, PA. Both
cells were incubated for 24 hrs. Finally, supernatants were
collected and IL-12p70 levels were measured using an
ELISA kit specific for human IL-12p70 (Endogen,
Woburn, MA).
Tumor antigens and other antigens in tumor tissues prior
to vaccination
High-grade glioma tissues were obtained from patients
who gave written informed consent. The expression of
tumor antigens including MAGE-A1, A3, WT-1, HER2
and gp100 was investigated using a non-quantitative RT-
PCR and an immunohistochemical (IHC) analysis as
described previously [22]. The primer sequences used
were 5’-CGGCCGAAGGAACCTGACCCAG-3’ and 5’-
GCTGGAACCCTCACTGGGTTGCC-3’ for MAGEA-1,
5’-TGGAGGACCAGAGGCCCCC-3’ and 5’-GGACGA
TTATCAGGAGGCCTGC-3’ for MAGE-A3, 5’-TCTT
CAGAGGCATTCAGGATGTGC-3’ and 5’-GAGTCCT
GGTGTGGGTCTTCAGGT-3’ for WT-1, 5’-CTATGG
CTGCCTCTTAGACCATGTCC-3’ and 5’-AAAGTCAT
CAGCTCCCACACAGTCAC-3’ for HER2, 5’-TAGTG
GAACCCTGATCTCTC-3’ and 5’-TCAGGGATAGG-
TAGCTCTCT-3’ for gp100, and 5’-GGCTACAGCT
TCACCACCAC-3’ and 5’-GTACTTGCGCTCAGGAG
GAG-3’ for beta-actin. HLA-class I protein expression was
also evaluated using an IHC analysis. Antibodies against
MAGE-A1 (Thermo scientific, Flemont, CA), MAGE-
A3 (Abnova, Taipei, Taiwan), WT-1 (DakoCytomation,
Glostrup, Denmark), HER1 (DakoCytomation), gp100
((DakoCytomation) and human HLA class I (Hokudo
Co. Ltd., Sapporo, Japan) were used as the primary anti-
body and a goat anti-mouse or anti-rabbit IgG antibody,
as the secondary antibody. Horseradish peroxidase (HRP)
and hydrogen peroxide were utilized for color develop-
ment according to the manufacturer`s instructions
(Vectastatin kit, Vector Lab., CA).
Clinical and immunological monitoring
Clinical assessment was performed using RECIST cri-
teria [23] as follows; complete response (CR) : disappear-
ance of lesions at 4 wks, partial response (PR): 30%
decrease in sums of longest diameters at 4 wks, stable
disease (SD): neither PR nor PD criteria met, progressive
disease (PD): 20% increase in sums of longest diameters.
Clinical response was rated as maximal through the DC
vaccinations. The patients received up to 10 injections
on the condition that at least one measurable lesion
showed more than a SD response and/or an ELISPOT
assay performed after 4 injections indicated a positive
response for more than 1 peptide. Adverse effects were
evaluated according to the NCI Common toxicity criteria
after 4 DC injections. Peripheral blood mononuclear cell
(PBMC) samples were harvested before and 29, 78, 134 and
Table 2 Tumor antigen and HLA-class I expression in
resected tumors
Patient hHLA-typing Tumor antigen
expression
HLA-class Ia
1 A*2402 N. D. N. D. b
2 A*2402 5/5 (M1, M3, HER2,
gp100, WT-1)
++
3 A*2402 5/5 +
4 A*2402 N. D. N. D.
5 A*2402 3/5 (M3, HER2, WT-1) +
6 A*2402 5/5 +
7 A*0201 5/5 +
8 A*2402 N. D. N. D.
9 A*2402 5/5 +
aHLA-class I expression was checked on IHC, b N. D. ; not done.
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monitoring. All patients were followed regularly through-
out, and an MRI was performed every 2 to 3 months du-
ring the vaccination period.
ELISPOT assay
The ELISPOT assay was performed using PBMCs drawn
prior to vaccination and after 4 DC injections. Briefly,
PBMCs were incubated in a 24-well culture plate and
divided into non-adherent and adherent cells. Adherent
cells were treated with a peptide cocktail and β2-micro-
globulin, and co-cultured with non-adherent cells in the
presence of IL-2 and IL-7. On day7, non-adherent cells
were re-stimulated with peptide-pulsed adherent cells.
On day14, responder cells (5×104/well) were stimulated
with HLA-A2 or A24 peptides in a 96-well culture plate
coated with anti-IFN-γ antibody (MABTECH AB,
Nacka, Sweden) overnight. Finally, positive spots stained
with anti-IFN-γ antibody were measured using the KS
ELISPOT system (Carl Zeiss AG, Overkochen, Germany).
A HLA-A2- (GILGFVFTL) or A24-restricted CMVpp65
peptide (RYSIFFDY) was used as a positive control. The
spot number per well of peptide-stimulated CTLs was
compared to that of a negative well without peptide using
Student’s paired two-tailed t-test.
Intracellular cytokine staining
PBMCs were stimulated with 25 ng/ml of PMA (Sigma)
and 1 μg/ml of ionomycin (Sigma) for 5hrs in a 96-well
culture plate. After the stimulation, cells were stained
with FITC-anti-CD4 MoAb, and subsequently intracellu-
lar staining was performed with fix/permealization buf-
fer and PE-labeled anti-IFN-γ or anti-IL-4 MoAb
(Pharmingen,San Diego, CA). Finally, the ratio of Th1
(IFN-γ+) and Th2 (IL-4+) was calculated in PBMC sam-
ples obtained from patients.
DTH reactions
The HLA-A2 or A24 peptide solution and KLH at a
dose of 50 μg/ml were injected intradermally into the
forearm and the redness and induration at the injection
site were measured on days 29, 78, 134 and 190 after the
1st DC injection. 1 × 106 DCs treated with peptides were
added to DTH antigens after the start of the vaccination.
PPD was used as a positive control.
Statistical analysis
Statistical differences were analyzed using Student’s
paired two-tailed t-test. Values of p < 0.05 were consi-
dered significant.
Results
Patient characteristics The nine patients consisted of 7
males and 2 females, and mean age was 48.6 ± 16.4.Eight cases were HLA-A*2402 in genotype. Previous
therapy including ST, RT and chemotherapy (CT) was
performed in all patients. Histologically, there were 6
GBMs (WHO grade IV), 1 anaplastic astrocytoma (AA)
(grade III) and 1 anaplastic oligodendroglioma (AO)
(grade III) (Table 1).
Characterization of tumor antigen expression
An analysis of tumor antigen expression by RT-PCR and
IHC was performed in 6 evaluable cases. The antigen
expression was determined as positive, when either the
RT-PCR or IHC analysis was positive. All 5 tumor anti-
gens including MAGE-A1, -A3, HER2, gp100 and WT1
were positive in 5 cases except for patient 5 in which 3
antigens were identified in the tumor (Table 2). A repre-
sentative case of tumor expression analyzed by IHC,
patient 6, showed strong reactions to MAGE-A1, MAGE-
A3, and WT-1 antigens (Figure 1). The HLA-class I pro-
tein was positive in all cases, but the expression level was
different (data not shown).
DC production efficiency and characterization
Through gradient-centrifugation using Optiprep, the fre-
quency of CD14+ cells improved from 11.9% to 44.6%,
an increase of 4 fold (Table 3). The mean percentage of
DCs rated as lin-HLA-DR+ (Figure 2) and the DC1/DC2
ratio in glioma patients was 56.9 ± 19.1% and 35.6, re-
spectively, comparable to a previous phase I DC vaccine
study for metastatic melanomas. Comparing obtained
DC numbers to starting total cell numbers, the recovery
rate was determined as 8.79%, also comparable to the
previous study. Importantly, IL-12p70 levels produced
by DCs through CD40 ligand stimulation were remark-
ably high, more than 1,000 pg/ml, which indicated a fully
mature phenotype of the obtained DCs (Table 3). The
frequencies of the DC-related markers were determined
in gated lin-HLA-DR+ cells as follows; CD1a 16.3 ± 13.2%,
H & E stain Control MAGE-A1
MAGE-A3 WT-1
Figure 1 Immunohistochemical analysis of tumor antigens in resected tumor tissue from patient 6. Many positively stained pleomorphic
giant cells and their processes were shown. Each primary antibody against MAGE-A1, MAGE-A3, and WT-1 was used at a dilution of 1:10 ~ 1:100.
Mouse IgG antibody was used as a control. H & E stain; hematoxylin and eosin stain. Magnification ×400.
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CD83 44.7 ± 19.5%, CD86 99.6 ± 0.3%, CD205 73.9 ±
12.1%, CD207 92.3 ± 11.6%, HLA-class I 99.0 ± 1.2%, which
also demonstrated the fully mature phenotype (Table 4).
ELISPOT assay
CTL precursors against synthetic peptides were recog-
nized after the vaccination in 6 evaluable cases (Table 5).
Notably, 3 cases demonstrated CTL responses to more
than 3 peptides, and patient 2 showed a durable SD
without relapse for 34 months after the start of the vaccin-
ation, with a remarkably high CTL response to 4 HLA-
A24 peptides (Figure 3).
Th1 and Th2 balance after DC vaccination
In all 9 cases, the balance of Th1 and Th2 shifted more
to Th1 (mean ratio; 13.1 ± 7.3) before DC injections
(Table 5). Unfortunately, PBMC samples were not
obtained after the vaccinations in 8 cases. No correlation
of Th1/Th2 ratio to ELISPOT responses was observed.
DTH
Positive DTH tests were verified in 4 patients against all
peptides, 4 against DCs treated with peptides, and 4
against KLH (Table 5). Specifically, 2 patients (2 and 9)




cell no. (×109 )
Optiprep (CD14+ %) DC rate (%)
(lin-HLA-DRpre post
9 6.50±3.4 11.9±9.4 44.6±21.8 56.1±19.0
* The frequency of DCs was determined from lineage (CD3, CD14, CD16, CD19, CD2very strong reactions. Surprisingly in patient 2, after the
start of the vaccination, the responses to each peptide,
KLH and DCs increased to a plateau, and responses to
KLH and DCs remained highly positive even after more
than 2 years, despite that the response to peptides went
down after the vaccination ceased (Figure 4).
Adverse effects of the DC vaccine
Safety was assessed after 4 DC injections in all 9 cases.
Mild hepatic dysfunction (grade II) was seen in 1 case,
however it was only temporary and disappeared in spite
of the continuance of DC injections. No clinical symp-
toms of autoimmune disease were found (Table 5).
Clinical response
Clinical response was rated as maximal throughout the
DC vaccinations. Seven of 8 showed PD due to a rapid
progression of the disease (Table 5). Patient 2 demon-
strated a long SD after total resection for more than 2
years, in which strong CTL and DTH responses were
recognized throughout the vaccination period.
Discussion
Since sipuleucel-T (Provenge, Dendreon), an autologous
cellular immunotherapy, was approved by the U.S.










4.22±1.7 8.79±5.1 35.6±39.6 1025±443
0, CD56)-HLA-DR+ cell population.
A B
C D
Figure 2 Characterization of cultured α-type-1 DCs from patient 6 by flow cytometry. The mean percentage of DCs rated as lin-HLA-DR+ is
shown in B. A; dot gram of whole cultured cells. The DC gate is shown as a large and widely distributed population. B; DC population
determined as lin-HLA-DR+ cells. C; DC2 (CD123+HLA-DR+) and D; DC1 (CD11c+HLA-DR+) is shown, respectively.
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metastatic castration-resistant prostate cancer patients
has attracted much attention despite a low rate of
clinical response [24,25].
In early phase trials, sipuleucel-T showed good safety,
but a weak anti-tumor response which was not impressive
compared with chemotherapeutic regimens. However, the
last double-blind, placebo-controlled, multicenter phase
III trial of the sipuleucel-T vaccine clearly demonstrated a
significant survival benefit for metastatic prostate cancer.
Based on these observations, the major focus of cancer-
specific DC-based immunotherapy has been shifting
toward the improvement of overall survival and QOL
including performance status.
With regard to the development of DC-based immuno-
therapy, many studies have been performed on relapsed or
advanced high-grade gliomas since 2000 [26-29]. In most
studies, monocyte-derived DCs treated with autologousTable 4 Phenotypical analysis of α-type-1 DCs after a 7-day c






* Each value represents the frequency of marker-positive cells in lineage-HLA-DR+ gtumor lysate have been utilized, and a beneficial effect on
overall survival to some degree was obtained, but the
objective response rate was still low. Reasons for the use
of tumor lysate include; i) poor identification of high-
grade glioma-specific tumor antigens, ii) independence of
tumor lysate from HLA-restriction, and iii) practicality in
terms of personalized medicine. However, disadvantages
include the absence of an evaluable target antigen and im-
munological monitoring methods, and no validated proto-
col for lysate production from tumor tissues. Taking these
issues into consideration, immunogenic synthetic peptides
still seem to have an advantage over tumor lysate.
DC maturation status is becoming an important issue,
and IL-12p70-producing ability would be a key factor to
a successful DC vaccine for high-grade glioma [30-33].
Mailliard et al. reported that very efficient IL-12-producing
DCs, so-call α-type-1 polarizing DCs, can be obtained by
combining cytokines like IL-1β, TNF-α, IFN-α, IFN-γ andulture






92.3±11.6 HLA-class I 99.0±1.2
ated population.
Table 5 Immunological monitoring in high-grade glioma patients
Patient no. DC injection (times) Side effect ELISPOT DTH Th1/Th2 balancea Response
Peptide DC KLH
1 1×107(12) 1/5 (MAGE-1) + + 9.38 PD
2 1×107(24) 4/5 (WT1-1, 1–2, MAGE-1, 3) ++ ++ +++ 0.3 SD
3 1×107(4) N. D.b 9.67 PD
4 2×107(5) Hepatic (II) 3/5 (WT1-1, 1–2, MAGE-3) 4.09 PD
5 2×107(6) 0 + 6.07 PD
6 2×107(4) 0 2.77 PD
7 5×107(7) 1/5 (gp100) + 7.08 PD
8 5×107(6) 3/5 (WT1-2, HER2, MAGE-3) 71.4 PD
9 5×107(6) 2/5 (MAGE-1, 3) ++ + + 7.55 PD
a The value shows Th1/Th2 ratio prior to DC vaccination. b N. D. ; not done. PD ; progressive disease, SD ; stable disease.
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remarkably stronger CTLs than conventional methods
[17]. Based on these observations, Okada et al. [18] applied
α-type-1 polarizing DCs to a phase I/II clinical trial for 22
cases of HLA-A2+ high-grade glioma, where HLA-A2 pep-
tides like EphA2, Il-13R-a2, YKL-40 and gp100 were used,
and obtained 2 objective responders and 9 cases with
progression-free survival for at least 12 months. These
results demonstrated that peptide-cocktail-based α-type-1
polarizing DCs were a better therapeutic tool than tumor-
lysate-based DCs. More importantly, IL-12 production by
α-type-1 polarizing DCs was shown to be positively corre-
lated with the time to progression, which indicated IL-12-















Figure 3 Effect of DC vaccines on tumor progression and CTL inducti
as 34 months by DC vaccines after surgical resection as revealed by MRI. B
assay. The spot number per well of peptide-stimulated CTLs was compared
two-tailed t-test. Statistically significant compared to no peptide, *; P < 0.05In the present study, we also utilized α-type-1 polari-
zing DCs for HLA-A24+ recurrent high-grade glioma
patients in a phase I trial. DC production was performed
in a clean-air barriered good manufacturing practice
(GMP) cell processing facility, and under standard ope-
ration procedures (SOP) for DC production according to
institutional GMP-based guidelines. First, as to DC pro-
duction efficiency, the mean number of obtained DCs
per patient and mean DC yield was 4.22 x108 and 8.79%,
respectively which was comparable to the yield (3.4%)
reported by Szmania et al. [34].
Previously, we reported a phase II trial of a DC vaccine
against HLA-A24+ metastatic melanoma, and demon-









on in patient 2. A; Maintenance of progression-free status for as long
; Remarkable CTL activity after 8 DC vaccines as revealed by ELISPOT
to that of a negative well without peptide using Student’s paired
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Figure 4 Long-term activation of DTH to peptides and KLH through the course of DC vaccinations in patient 2. The responses to each
peptide, KLH, and DCs increased to a plateau, and responses to KLH and DCs remained highly positive even more than 2 years after the start of
the vaccination, despite that the response to the peptides went down after the vaccinations ceased.
Akiyama et al. BMC Cancer 2012, 12:623 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/623associated with the prognosis [35]. This result suggests
the total dose of qualified DCs to be a key factor to a suc-
cessful vaccination. The longer patients are given DC vac-
cines, the better their prognosis will be. Therefore, the
yield of DCs, namely the recovery rate from a leukapher-
esis product, is important. Second, IL-12 production levels
were 1025 ± 443 pg per 105 DCs, higher than the
levels (< 500 pg) reported by Okada et al. [18]. A total of
74 DC injections were well-tolerated without significant
adverse effects, and finally, safety and feasibility were veri-
fied. We also found a SD case with a relapse-free period of
more than 2 years after tumor resection, which interest-
ingly showed long positive DTH reactions against pep-
tides, KLH and even DCs treated with peptides.
Recent progress in the clinical trial of DC vaccines
against malignant glioma should be addressed. First, as
Ardon et al. reported, the integration of autologous DC-
based immunotherapy into the treatment of newly diag-
nosed GBM patients is ongoing [11]. The efficacy of DC
vaccines in combination with RT and CT might be poten-
tiated in such a study. Second, the potential of DC vaccines
in combination with chemotherapy has been stressed.
Wheeler et al. [36] demonstrated a strong link between the
predominant T-cell effectors and chemosensitivity in GBM
tumors. In the near future, to improve the vaccine-induced
benefits and relapse-free period, optimal combinations of
DC vaccines and chemotherapy need to be developed.
Finally, given the success of sipuleucel-T trials, multi-
centered phase III randomized studies of specific peptide-
or tumor lysate-treated DCs against high-grade glioma are
strongly recommended.
Conclusions
In the present study, we investigated the effect of immuno-
therapy based on α-type-1 polarizing DCs on high-gradeglioma patients with mainly HLA-A*2402. Nine patients
with high-grade glioma (1 case of HLA-A*0201, 8 of
A*2402) were enrolled into a phase I study and given
HLA-A2 or A24-peptide cocktail-pulsed mature DCs,
which produced a large amount of IL-12. Positive im-
munological responses to peptides in an ELISPOT assay
were found in 6 cases, and positive skin tests to peptide-
pulsed DC and KLH were recognized in 4 cases. The
clinical response to DC injections was 1SD and 8 PD.
All 76 DC injections were safely administered to
patients. These results suggested that peptide cocktail-
treated α-type-1 DC-based immunotherapy was feasible,
and had potential as a therapeutic tool against HLA-A24+
high-grade glioma.
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